ADC THERAPEUTICS SA (ADCT)
CH0499880968 - Common Stock
Wednesday's session: top gainers and losers
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Which stocks are experiencing notable movement on Wednesday?
Which stocks are experiencing notable movement on Wednesday?
Wednesday Sector Laggards: Shipping, Drugs
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
/PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma
/PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
Which stocks are moving on Friday?
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Let's take a look at the stocks that are in motion in today's session.
Which stocks are experiencing notable movement on Friday?
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
/PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), today announced that it will host a conference call and live webcast on Wednesday, December 11, 2024, at 8:30...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
/PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update
/PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported...
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting
/PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
ADC Therapeutics to Present at November Investor Conferences
/PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
/PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
/PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
ADC Therapeutics gewährt neuen Mitarbeitern Zuteilungen im Rahmen des Anreizplans
LAUSANNE, Schweiz, Oct. 02, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), ein weltweit führendes und innovatives Unternehmen im Bereich der...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, Oct. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of...
ADC Therapeutics gewährt neuen Mitarbeitern Zuteilungen im Rahmen des Anreizplans
LAUSANNE, Schweiz, Sept. 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), ein weltweit führendes und innovatives Unternehmen im Bereich der...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of...
ADC Therapeutics to Present at Upcoming Investor Conferences
ADC Therapeutics to Present at Upcoming Investor Conferences
LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of...
ADC Therapeutics hält Vorträge auf bevorstehenden Investorenkonferenzen
LAUSANNE, Schweiz, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), ein weltweit führendes und innovatives Unternehmen im Bereich der...
ADC Therapeutics berichtet über Finanzergebnisse des zweiten Quartals 2024 und gibt aktuelle Informationen zum Geschäftsbetrieb bekannt
ZYNLONTA® – Nettoumsatz von 17,0 Mio. USD im 2. Quartal 2024; kommerzielle Rentabilität in der ersten Hälfte des Jahres 2024 erreicht Rekrutierung für...
ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q2 2024
ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024 LOTIS-7 trial enrollment on track with...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of...
ADC Therapeutics gewährt neuen Mitarbeitern Zuteilungen im Rahmen des Anreizplans
LAUSANNE, Schweiz, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), ein weltweit führendes Unternehmen im kommerziellen Stadium und...
ADC Therapeutics veranstaltet am 6. August 2024 eine Telefonkonferenz zu den Finanzergebnissen des zweiten Quartals 2024
LAUSANNE, Schweiz, July 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), ein weltweit führendes, in der Kommerzialisierung tätiges...
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
LAUSANNE, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of...
7 Growth Stocks to Buy for Under $5 for Massive Gains
Although growth stocks under $5 are inherently risky and unpredictable, their very nature also facilitates robust upside potential.
ADC Therapeutics gewährt neuen Mitarbeitern Zuteilungen im Rahmen des Anreizplans
LAUSANNE, Schweiz, July 02, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) hat heute bekanntgegeben, dass das Unternehmen sechs neuen...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, July 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to...
ADC Therapeutics tritt demnächst den Indizes Russell 2000® und Russell 3000® bei
LAUSANNE, Schweiz, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) hat heute bekanntgegeben, dass das Unternehmen nach Abschluss der...
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell...